Hot Spaces Track To Offer Broad Array Of Late-Stage Partnering Opportunities
Without a therapeutic category to narrow down all the options, Catherine Staughton faced quite a challenge in pulling together the 10 product candidates that comprise the Hot Spaces track at this year’s Windhover Therapeutic Areas Partnership conference.
You may also be interested in...
Lux Biosciences will have to do another clinical trial - on top of three already completed Phase III studies - for FDA to consider approving its uveitis treatment Luveniq (voclosporin), the agency said in a "complete response" letter announced Aug. 4
Effective medical device regulation supports both safety and innovation needs. This article assesses how well the US FDA and the Australian TGA achieve this balance.